{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T05:33:56Z","timestamp":1793338436050,"version":"4.5.0"},"reference-count":155,"publisher":"Bentham Science Publishers Ltd.","issue":"10","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CPPS"],"published-print":{"date-parts":[[2026,12]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>One of the main causes of infectious disease-related deaths globally is\nMycobacterium tuberculosis (M.tb), the causative agent of tuberculosis (TB). Novel treatment\nstrategies are now much more urgent due to the emergence of Extensively Drug-Resistant (XDR)\nand multidrug-resistant (MDR) strains. The purpose of this study is to investigate the potential of\nantimicrobial peptides (AMPs) as TB adjunctive therapeutic agents, with an emphasis on their immunomodulatory\nand direct antimycobacterial effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A summary of how antimicrobial peptides (AMPs) work was carried out, including how\nthey can damage bacterial membranes and obstruct intracellular processes. Furthermore, the review\nevaluated how AMPs affect host immune responses, including enhanced phagosome-lysosome\nfusion, induction of autophagy, and cytokine production.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Many AMPs have shown strong antimycobacterial activity in vitro and in vivo, including\ndefensins, cathelicidins (like LL-37), and synthetic analogues. Even with these encouraging outcomes,\nissues such as peptide stability and efficient delivery still stand in the way of clinical use.\nPotential remedies for these restrictions are offered by advances in peptide engineering, nanoparticle-\nbased delivery methods, and structure-activity relationship (SAR) research.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion:<\/jats:title>\n                    <jats:p>Recent advances in peptide engineering, nanoparticle-based delivery systems, and\nstructure-activity relationship (SAR) studies offer promising strategies to overcome the limitations\nassociated with AMP stability, bioavailability, and targeted delivery. These developments significantly\nenhance the translational potential of AMPs for TB therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Because of their distinct mechanisms of action and capacity to overcome drug resistance,\nAMPs offer a novel and promising approach to the treatment of tuberculosis. Global TB\ncontrol efforts could be greatly aided by ongoing research into maximizing their safety and effectiveness.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/0113892037433604260409094048","type":"journal-article","created":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T17:52:21Z","timestamp":1776621141000},"page":"926-945","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeting Drug-Resistant Tuberculosis with Antimicrobial Peptides: Opportunities and Challenges"],"prefix":"10.2174","volume":"27","author":[{"given":"Asad","family":"Ahmad","sequence":"first","affiliation":[{"name":"Faculty of Pharmacy, Integral University, Lucknow, (UP), India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rufaida","family":"Wasim","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, Integral University, Lucknow, (UP), India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anas","family":"Islam","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, Integral University, Lucknow, (UP), India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akash","family":"Srivastava","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, Integral University, Lucknow, (UP), India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/S0140-6736(19)32045-8","volume":"394","author":"Reuter A.","year":"2019","unstructured":"Reuter A.; Hughes J.; Furin J.; Challenges and controversies in childhood tuberculosis. Lancet  2019,394(10202),967-978","journal-title":"Lancet"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1055\/a-2331-7061","volume":"74","author":"Ahmad A.","year":"2024","unstructured":"Ahmad A.; Akhtar J.; Ahmad M.; Khan M.I.; Wasim R.; Islam A.; Singh A.; Bedaquiline: An Insight Into its clinical use in multidrug-resistant pulmonary tuberculosis. Drug Res (Stuttg)  2024,74(6),269-279","journal-title":"Drug Res (Stuttg)"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1038\/507S4a","volume":"507","author":"Bourzac K.","year":"2014","unstructured":"Bourzac K.; Infectious disease: Beating the big three. Nature  2014,507(7490),S4-S7","journal-title":"Nature"},{"key":"ref=4","unstructured":"World Health Organization. Global Tuberculosis Report, 2024. Available from:  https:\/\/www.who.int\/publications\/i\/item\/9789240013131"},{"key":"ref=5","first-page":"509","volume":"30","author":"Kurz S.G.","year":"2016","unstructured":"Kurz S.G.; Furin J.J.; Bark C.M.; Drug-resistant tuberculosis: Challenges and progress. Infectious Disease Clinics  2016,30(2),509-522","journal-title":"Infectious Disease Clinics"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41572-024-00504-2","volume":"10","author":"Dheda K.","year":"2024","unstructured":"Dheda K.; Mirzayev F.; Cirillo D.M.; Udwadia Z.; Dooley K.E.; Chang K.C.; Omar S.V.; Reuter A.; Perumal T.; Horsburgh C.R.; Murray M.; Lange C.; Multidrug-resistant tuberculosis. Nat Rev Dis Primers  2024,10(1),22","journal-title":"Nat Rev Dis Primers"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"bay025","DOI":"10.1093\/database\/bay025","volume":"2018","author":"Usmani S.S.","year":"2018","unstructured":"Usmani S.S.; Kumar R.; Kumar V.; Singh S.; Raghava G.P.S.; AntiTbPdb: A knowledgebase of anti-tubercular peptides. Database (Oxford)  2018,2018,bay025","journal-title":"Database (Oxford)"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/j.biotechadv.2016.05.007","volume":"34","author":"Silva J.P.","year":"2016","unstructured":"Silva J.P.; Appelberg R.; Gama F.M.; Antimicrobial peptides as novel anti-tuberculosis therapeutics. Biotechnol Adv  2016,34(5),924-940","journal-title":"Biotechnol Adv"},{"key":"ref=9","doi-asserted-by":"publisher","unstructured":"Muhammad, N; Ansar, W; Ullah, A; Liaqat, I; Nazir, Z. A review on diversity, mechanism of action and evolutionary significance of antimicrobial peptides. Futurist Biotechnol., 2024, 4(2), 2-9.","DOI":"10.54393\/fbt.v4i02.99"},{"key":"ref=10","first-page":"10","volume":"2","author":"Pai M.","year":"2016","unstructured":"Pai M.; Behr M.A.; Dowdy D.; Dheda K.; Divangahi M.; Boehme C.C.; Ginsberg A.; Swaminathan S.; Spigelman M.; Getahun H.; Nature reviews disease primers. Tuberculosis (Edinb)  2016,2(16076),10-38","journal-title":"Tuberculosis (Edinb)"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"e00069-18","DOI":"10.1128\/CMR.00069-18","volume":"32","author":"Franco-Paredes C.","year":"2018","unstructured":"Franco-Paredes C.; Marcos L.A.; Henao-Mart\u00ednez A.F.; Rodr\u00edguez-Morales A.J.; Villamil-G\u00f3mez W.E.; Gotuzzo E.; Bonifaz A.; Cutaneous mycobacterial infections. Clin Microbiol Rev  2018,32(1),e00069-18","journal-title":"Clin Microbiol Rev"},{"key":"ref=12","author":"Ivie J.","year":"2024","unstructured":"Ivie J.;  Determining the Major Genetic Regulators of Mycobacterium tuberculosis-induced Cytokine Expression in Monocytes and Macrophages with a Cellular GWAS PhD Thesis, University of Washington, 2024  2024","journal-title":"Determining the Major Genetic Regulators of Mycobacterium tuberculosis-induced Cytokine Expression in Monocytes and Macrophages with a Cellular GWAS PhD Thesis, University of Washington, 2024"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"e01237-25","DOI":"10.1128\/mbio.01237-25","volume":"16","author":"Mohapatra A.","year":"2025","unstructured":"Mohapatra A.; Norris B.A.; Howard Z.; Ernst J.D.; CCR2 recruits monocytes to the lung, while CX3CR1 modulates positioning of CD11c  cells in the lymph node during pulmonary tuberculosis. MBio  2025,16(7),e01237-25","journal-title":"MBio"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1007\/s00018-019-03353-5","volume":"77","author":"Chai Q.","year":"2020","unstructured":"Chai Q.; Lu Z.; Liu C.H.; Host defense mechanisms against Mycobacterium tuberculosis. Cell Mol Life Sci  2020,77(10),1859-1878","journal-title":"Cell Mol Life Sci"},{"key":"ref=15","doi-asserted-by":"publisher","unstructured":"Qualls, J.E.; Murray, P.J. Immunometabolism within the tuberculosis granuloma: Amino acids, hypoxia, and cellular respiration. Semin. Immunopathol., 2016, 38, 139\u2013152.","DOI":"10.1007\/s00281-015-0534-0"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"2334","DOI":"10.3390\/microorganisms10122334","volume":"10","author":"Salina E.G.","year":"2022","unstructured":"Salina E.G.; Makarov V.; Mycobacterium tuberculosis dormancy: How to fight a hidden danger. Microorganisms  2022,10(12),2334","journal-title":"Microorganisms"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.3390\/antibiotics11101431","volume":"11","author":"Arrigoni R.","year":"2022","unstructured":"Arrigoni R.; Ballini A.; Topi S.; Bottalico L.; Jirillo E.; Santacroce L.; Antibiotic resistance to Mycobacterium tuberculosis and potential use of natural and biological products as alternative anti-mycobacterial agents. Antibiotics (Basel)  2022,11(10),1431","journal-title":"Antibiotics (Basel)"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1017\/S0031182016002377","volume":"145","author":"Abrahams K.A.","year":"2018","unstructured":"Abrahams K.A.; Besra G.S.; Mycobacterial cell wall biosynthesis: a multifaceted antibiotic target. Parasitology  2018,145(2),116-133","journal-title":"Parasitology"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1093\/cid\/cit790","volume":"58","author":"Mangtani P.","year":"2014","unstructured":"Mangtani P.; Abubakar I.; Ariti C.; Beynon R.; Pimpin L.; Fine P.E.M.; Rodrigues L.C.; Smith P.G.; Lipman M.; Whiting P.F.; Sterne J.A.; Protection by BCG vaccine against tuberculosis: A systematic review of randomized controlled trials. Clin Infect Dis  2014,58(4),470-480","journal-title":"Clin Infect Dis"},{"key":"ref=20","first-page":"657","volume":"51","author":"Bi K.","year":"2022","unstructured":"Bi K.; Cao D.; Ding C.; Lu S.; Lu H.; Zhang G.; Zhang W.; Li L.; Xu K.; Zhang Y.; The past, present and future of tuberculosis treatment. Zhejiang Da Xue Xue Bao Yi Xue Ban (J Zhejiang Uni Med Sci)  2022,51(6),657-668","journal-title":"Zhejiang Da Xue Xue Bao Yi Xue Ban (J Zhejiang Uni Med Sci)"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.3390\/app10072278","volume":"10","author":"Vilch\u00e8ze C.","year":"2020","unstructured":"Vilch\u00e8ze C.; Mycobacterial cell wall: A source of successful targets for old and new drugs. Appl Sci (Basel)  2020,10(7),2278","journal-title":"Appl Sci (Basel)"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.jiph.2018.04.005","volume":"11","author":"Zaw M.T.","year":"2018","unstructured":"Zaw M.T.; Emran N.A.; Lin Z.; Mutations inside rifampicin-resistance determining region of rpoB gene associated with rifampicin-resistance in Mycobacterium tuberculosis. J Infect Public Health  2018,11(5),605-610","journal-title":"J Infect Public Health"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"e00070-19","DOI":"10.1128\/MMBR.00070-19","volume":"84","author":"Lamont E.A.","year":"2020","unstructured":"Lamont E.A.; Dillon N.A.; Baughn A.D.; The bewildering antitubercular action of pyrazinamide. Microbiol Mol Biol Rev  2020,84(2),e00070-19","journal-title":"Microbiol Mol Biol Rev"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.addr.2009.11.023","volume":"62","author":"Sosnik A.","year":"2010","unstructured":"Sosnik A.; Carcaboso \u00c1.M.; Glisoni R.J.; Moretton M.A.; Chiappetta D.A.; New old challenges in tuberculosis: Potentially effective nanotechnologies in drug delivery. Adv Drug Deliv Rev  2010,62(4-5),547-559","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"722","DOI":"10.3390\/microorganisms13040722","volume":"13","author":"Omoteso O.A.","year":"2025","unstructured":"Omoteso O.A.; Fadaka A.O.; Walker R.B.; Khamanga S.M.; Innovative strategies for combating multidrug-resistant tuberculosis: Advances in drug delivery systems and treatment. Microorganisms  2025,13(4),722","journal-title":"Microorganisms"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"277","DOI":"10.12701\/yujm.2020.00626","volume":"37","author":"Jang J.G.","year":"2020","unstructured":"Jang J.G.; Chung J.H.; Diagnosis and treatment of multidrug-resistant tuberculosis. Yeungnam Univ J Med  2020,37(4),277-285","journal-title":"Yeungnam Univ J Med"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3389\/fchem.2019.00043","volume":"7","author":"Haney E.F.","year":"2019","unstructured":"Haney E.F.; Straus S.K.; Hancock R.E.W.; Reassessing the host defense peptide landscape. Front Chem  2019,7,43","journal-title":"Front Chem"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.tube.2014.03.011","volume":"94","author":"Padhi A.","year":"2014","unstructured":"Padhi A.; Sengupta M.; Sengupta S.; Roehm K.H.; Sonawane A.; Antimicrobial peptides and proteins in mycobacterial therapy: Current status and future prospects. Tuberculosis (Edinb)  2014,94(4),363-373","journal-title":"Tuberculosis (Edinb)"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"e216","DOI":"10.1016\/S1473-3099(20)30327-3","volume":"20","author":"Magana M.","year":"2020","unstructured":"Magana M.; Pushpanathan M.; Santos A.L.; Leanse L.; Fernandez M.; Ioannidis A.; Giulianotti M.A.; Apidianakis Y.; Bradfute S.; Ferguson A.L.; Cherkasov A.; Seleem M.N.; Pinilla C.; de la Fuente-Nunez C.; Lazaridis T.; Dai T.; Houghten R.A.; Hancock R.E.W.; Tegos G.P.; The value of antimicrobial peptides in the age of resistance. Lancet Infect Dis  2020,20(9),e216-e230","journal-title":"Lancet Infect Dis"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.2174\/1568026620666200427091454","volume":"20","author":"Gaglione R.","year":"2020","unstructured":"Gaglione R.; Pizzo E.; Notomista E.; de la Fuente-Nunez C.; Arciello A.; Host defence cryptides from human apolipoproteins: Applications in medicinal chemistry. Curr Top Med Chem  2020,20(14),1324-1337","journal-title":"Curr Top Med Chem"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"194","DOI":"10.3389\/fcimb.2016.00194","volume":"6","author":"Mahlapuu M.","year":"2016","unstructured":"Mahlapuu M.; H\u00e5kansson J.; Ringstad L.; Bj\u00f6rn C.; Antimicrobial peptides: An emerging category of therapeutic agents. Front Cell Infect Microbiol  2016,6,194","journal-title":"Front Cell Infect Microbiol"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"475","DOI":"10.3390\/antibiotics11040475","volume":"11","author":"Ali W.","year":"2022","unstructured":"Ali W.; Elsahn A.; Ting D.S.J.; Dua H.S.; Mohammed I.; Host defence peptides: A potent alternative to combat antimicrobial resistance in the era of the covid-19 pandemic. Antibiotics (Basel)  2022,11(4),475","journal-title":"Antibiotics (Basel)"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1093\/femsre\/fuv008","volume":"40","author":"Sohlenkamp C.","year":"2016","unstructured":"Sohlenkamp C.; Geiger O.; Bacterial membrane lipids: Diversity in structures and pathways. FEMS Microbiol Rev  2016,40(1),133-159","journal-title":"FEMS Microbiol Rev"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2174\/1568026615666150703121700","volume":"16","author":"Lee T.H.N.","year":"2016","unstructured":"Lee T.H.N.; Hall K.N.; Aguilar M.I.; Antimicrobial peptide structure and mechanism of action: a focus on the role of membrane structure. Curr Top Med Chem  2016,16(1),25-39","journal-title":"Curr Top Med Chem"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"111198","DOI":"10.1016\/j.colsurfb.2020.111198","volume":"194","author":"Cao P.","year":"2020","unstructured":"Cao P.; Liu K.; Liu X.; Sun W.; Wu D.; Yuan C.; Bai X.; Zhang C.; Antibacterial properties of Magainin II peptide onto 304 stainless steel surfaces: A comparison study of two dopamine modification methods. Colloids Surf B Biointerfaces  2020,194,111198","journal-title":"Colloids Surf B Biointerfaces"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"100182","DOI":"10.1016\/j.crmicr.2023.100182","volume":"4","author":"Islam M.M.","year":"2023","unstructured":"Islam M.M.; Asif F.; Zaman S.U.; Arnab M.K.H.; Rahman M.M.; Hasan M.; Effect of charge on the antimicrobial activity of alpha-helical amphibian antimicrobial peptide. Curr Res Microb Sci  2023,4,100182","journal-title":"Curr Res Microb Sci"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"2201945","DOI":"10.1002\/adma.202201945","volume":"34","author":"Kang Z.","year":"2022","unstructured":"Kang Z.; Wang C.; Zhang Z.; Liu Q.; Zheng Y.; Zhao Y.; Pan Z.; Li Q.; Shi L.; Liu Y.; Spatial distribution control of antimicrobial peptides through a novel polymeric carrier for safe and efficient cancer treatment. Adv Mater  2022,34(23),2201945","journal-title":"Adv Mater"},{"key":"ref=38","doi-asserted-by":"publisher","unstructured":"Haney, E.F.; Mansour, S.C.; Hancock, R.E.W. Antimicrobial Peptides: An Introduction. In: Hansen, P. eds. Antimicrobial peptides. methods in molecular biology. New York, NY: Humana Press 2017.","DOI":"10.1007\/978-1-4939-6737-7_1"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"275","DOI":"10.3389\/fphar.2014.00275","volume":"5","author":"Vale N.","year":"2014","unstructured":"Vale N.; Aguiar L.; Gomes P.; Antimicrobial peptides: A new class of antimalarial drugs? Front Pharmacol  2014,5,275","journal-title":"Front Pharmacol"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"593215","DOI":"10.3389\/fmicb.2020.593215","volume":"11","author":"Assoni L.","year":"2020","unstructured":"Assoni L.; Milani B.; Carvalho M.R.; Nepomuceno L.N.; Waz N.T.; Guerra M.E.S.; Converso T.R.; Darrieux M.; Resistance mechanisms to antimicrobial peptides in gram-positive bacteria. Front Microbiol  2020,11,593215","journal-title":"Front Microbiol"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.tibtech.2011.05.001","volume":"29","author":"Nguyen L.T.","year":"2011","unstructured":"Nguyen L.T.; Haney E.F.; Vogel H.J.; The expanding scope of antimicrobial peptide structures and their modes of action. Trends Biotechnol  2011,29(9),464-472","journal-title":"Trends Biotechnol"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3390\/biom8010004","volume":"8","author":"Kumar P.","year":"2018","unstructured":"Kumar P.; Kizhakkedathu J.; Straus S.; Antimicrobial peptides: Diversity, mechanism of action and strategies to improve the activity and biocompatibility in vivo. Biomolecules  2018,8(1),4","journal-title":"Biomolecules"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"986","DOI":"10.3390\/ijms21030986","volume":"21","author":"Chung C.R.","year":"2020","unstructured":"Chung C.R.; Jhong J.H.; Wang Z.; Chen S.; Wan Y.; Horng J.T.; Lee T.Y.; Characterization and identification of natural antimicrobial peptides on different organisms. Int J Mol Sci  2020,21(3),986","journal-title":"Int J Mol Sci"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.3390\/molecules22081297","volume":"22","author":"Silva T.","year":"2017","unstructured":"Silva T.; Gomes M.; Immuno-stimulatory peptides as a potential adjunct therapy against intra-macrophagic pathogens. Molecules  2017,22(8),1297","journal-title":"Molecules"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"582779","DOI":"10.3389\/fmicb.2020.582779","volume":"11","author":"Huan Y.","year":"2020","unstructured":"Huan Y.; Kong Q.; Mou H.; Yi H.; Antimicrobial peptides: Classification, design, application and research progress in multiple fields. Front Microbiol  2020,11,582779","journal-title":"Front Microbiol"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.3389\/fimmu.2018.03128","volume":"9","author":"Varga J.F.A.","year":"2019","unstructured":"Varga J.F.A.; Bui-Marinos M.P.; Katzenback B.A.; Frog skin innate immune defences: Sensing and surviving pathogens. Front Immunol  2019,9,3128","journal-title":"Front Immunol"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"785","DOI":"10.3390\/ijms17050785","volume":"17","author":"Falanga A.","year":"2016","unstructured":"Falanga A.; Lombardi L.; Franci G.; Vitiello M.; Iovene M.; Morelli G.; Galdiero M.; Galdiero S.; Marine antimicrobial peptides: nature provides templates for the design of novel compounds against pathogenic bacteria. Int J Mol Sci  2016,17(5),785","journal-title":"Int J Mol Sci"},{"key":"ref=48","first-page":"3919","volume":"11","author":"Lei J.","year":"2019","unstructured":"Lei J.; Sun L.; Huang S.; Zhu C.; Li P.; He J.; Mackey V.; Coy D.H.; He Q.; The antimicrobial peptides and their potential clinical applications. Am J Transl Res  2019,11(7),3919-3931","journal-title":"Am J Transl Res"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1099\/jmm.0.000912","volume":"68","author":"Portell-Buj E.","year":"2019","unstructured":"Portell-Buj E.; Vergara A.; Alejo I.; L\u00f3pez-Gav\u00edn A.; Mont\u00e9 M.R.; San Nicol\u00e1s L.; Gonz\u00e1lez-Mart\u00edn J.; Tud\u00f3 G.; In vitro activity of 12 antimicrobial peptides against Mycobacterium tuberculosis and Mycobacterium avium clinical isolates. J Med Microbiol  2019,68(2),211-215","journal-title":"J Med Microbiol"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1080\/20477724.2016.1195036","volume":"110","author":"Findlay F.","year":"2016","unstructured":"Findlay F.; Proudfoot L.; Stevens C.; Barlow P.G.; Cationic host defense peptides; novel antimicrobial therapeutics against Category A pathogens and emerging infections. Pathog Glob Health  2016,110(4-5),137-147","journal-title":"Pathog Glob Health"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1093\/jac\/dku570","volume":"70","author":"Abedinzadeh M.","year":"2015","unstructured":"Abedinzadeh M.; Gaeini M.; Sardari S.; Natural antimicrobial peptides against Mycobacterium tuberculosis. J Antimicrob Chemother  2015,70(5),1285-1289","journal-title":"J Antimicrob Chemother"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"16","DOI":"10.2174\/1568026615666150703121518","volume":"16","author":"Malmsten M.","year":"2015","unstructured":"Malmsten M.; Interactions of antimicrobial peptides with bacterial membranes and membrane components. Curr Top Med Chem  2015,16(1),16-24","journal-title":"Curr Top Med Chem"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/s10989-020-10110-x","volume":"27","author":"Datta S.","year":"2021","unstructured":"Datta S.; Roy A.; Antimicrobial peptides as potential therapeutic agents: a review. Int J Pept Res Ther  2021,27(1),555-577","journal-title":"Int J Pept Res Ther"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.tim.2019.08.002","volume":"28","author":"Yang W.","year":"2020","unstructured":"Yang W.; Briegel A.; Diversity of bacterial chemosensory arrays. Trends Microbiol  2020,28(1),68-80","journal-title":"Trends Microbiol"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2014\/867381","volume":"2014","author":"Ebenhan T.","year":"2014","unstructured":"Ebenhan T.; Gheysens O.; Kruger H.G.; Zeevaart J.R.; Sathekge M.M.; Antimicrobial peptides: their role as infection-selective tracers for molecular imaging. BioMed Res Int  2014,2014(1),1-15","journal-title":"BioMed Res Int"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"R14","DOI":"10.1016\/j.cub.2015.11.017","volume":"26","author":"Zhang L.","year":"2016","unstructured":"Zhang L.; Gallo R.L.; Antimicrobial peptides. Curr Biol  2016,26(1),R14-R19","journal-title":"Curr Biol"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1039\/D3DD00186E","volume":"3","author":"Nedyalkova M.","year":"2024","unstructured":"Nedyalkova M.; Paluch A.S.; Vecini D.P.; Lattuada M.; Progress and future of the computational design of antimicrobial peptides (AMPs): bio-inspired functional molecules. Digital Discovery  2024,3(1),9-22","journal-title":"Digital Discovery"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"10957","DOI":"10.1007\/s11033-012-1997-x","volume":"39","author":"Ko\u015bciuczuk E.M.","year":"2012","unstructured":"Ko\u015bciuczuk E.M.; Lisowski P.; Jarczak J.; Strza\u0142kowska N.; J\u00f3\u017awik A.; Horba\u0144czuk J.; Krzy\u017cewski J.; Zwierzchowski L.; Bagnicka E.; Cathelicidins: family of antimicrobial peptides. A review. Mol Biol Rep  2012,39(12),10957-10970","journal-title":"Mol Biol Rep"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.3389\/fmicb.2020.01902","volume":"11","author":"Alford M.A.","year":"2020","unstructured":"Alford M.A.; Baquir B.; Santana F.L.; Haney E.F.; Hancock R.E.W.; Cathelicidin host defense peptides and inflammatory signaling: Striking a balance. Front Microbiol  2020,11,1902","journal-title":"Front Microbiol"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s00441-019-03098-4","volume":"379","author":"Cirone K.M.","year":"2020","unstructured":"Cirone K.M.; Lahiri P.; Holani R.; Tan Y.L.; Arrazuria R.; De Buck J.; Barkema H.W.; Cobo E.R.; Synthetic cathelicidin LL-37 reduces Mycobacterium avium subsp. paratuberculosis internalization and pro-inflammatory cytokines in macrophages. Cell Tissue Res  2020,379(1),207-217","journal-title":"Cell Tissue Res"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"8103","DOI":"10.3390\/ijms26168103","volume":"26","author":"Voronko O.E.","year":"2025","unstructured":"Voronko O.E.; Khotina V.A.; Kashirskikh D.A.; Lee A.A.; Gasanov V.A.; Antimicrobial peptides of the cathelicidin family: Focus on LL-37 and its modifications. Int J Mol Sci  2025,26(16),8103","journal-title":"Int J Mol Sci"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"8349712","DOI":"10.1155\/2020\/8349712","volume":"2020","author":"Yang B.","year":"2020","unstructured":"Yang B.; Good D.; Mosaiab T.; Liu W.; Ni G.; Kaur J.; Liu X.; Jessop C.; Yang L.; Fadhil R.; Yi Z.; Wei M.Q.; Significance of LL-37 on immunomodulation and disease outcome. BioMed Res Int  2020,2020(1),8349712","journal-title":"BioMed Res Int"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"284","DOI":"10.3390\/nu14020284","volume":"14","author":"White J.H.","year":"2022","unstructured":"White J.H.; Emerging roles of vitamin D-induced antimicrobial peptides in antiviral innate immunity. Nutrients  2022,14(2),284","journal-title":"Nutrients"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"e0138340","DOI":"10.1371\/journal.pone.0138340","volume":"10","author":"Mily A.","year":"2015","unstructured":"Mily A.; Rekha R.S.; Kamal S.M.M.; Arifuzzaman A.S.M.; Rahim Z.; Khan L.; Haq M.A.; Zaman K.; Bergman P.; Brighenti S.; Gudmundsson G.H.; Agerberth B.; Raqib R.; Significant effects of oral phenylbutyrate and vitamin D3 adjunctive therapy in pulmonary tuberculosis: a randomized controlled trial. PLoS One  2015,10(9),e0138340","journal-title":"PLoS One"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1111\/j.1365-2249.2010.04313.x","volume":"164","author":"Rivas-Santiago C.E.","year":"2011","unstructured":"Rivas-Santiago C.E.; Rivas-Santiago B.; Le\u00f3n D.A.; Casta\u00f1eda-Delgado J.; Hern\u00e1ndez Pando R.; Induction of \u03b2-defensins by  -isoleucine as novel immunotherapy in experimental murine tuberculosis. Clin Exp Immunol  2011,164(1),80-89","journal-title":"Clin Exp Immunol"},{"key":"ref=66","doi-asserted-by":"crossref","unstructured":"Kumari, A.; Mathur, G.; Sharma, G. Antimicrobial peptides in tuberculosis: Insights into the immunomodulatory mechanisms. Chem. Bio. Lett., 2025, 12(1), 1253.","DOI":"10.62110\/sciencein.cbl.2025.v12.1253"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"4495","DOI":"10.1128\/IAI.00936-15","volume":"83","author":"Torres-Juarez F.","year":"2015","unstructured":"Torres-Juarez F.; Cardenas-Vargas A.; Montoya-Rosales A.; Gonz\u00e1lez-Curiel I.; Garcia-Hernandez M.H.; Enciso-Moreno J.A.; Hancock R.E.W.; Rivas-Santiago B.; LL-37 immunomodulatory activity during Mycobacterium tuberculosis infection in macrophages. Infect Immun  2015,83(12),4495-4503","journal-title":"Infect Immun"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.3390\/microorganisms11082119","volume":"11","author":"Fern\u00e1ndez-De La Cruz E.","year":"2023","unstructured":"Fern\u00e1ndez-De La Cruz E.; Wessely-Szponder J.; Vi\u00f1as M.; Vinuesa T.; Merlos A.; Jorba M.; Espinal P.; Fust\u00e9 E.; Native Pig Neutrophil Products: Insights into Their Antimicrobial Activity. Microorganisms  2023,11(8),2119","journal-title":"Microorganisms"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"10225536231175237","DOI":"10.1177\/10225536231175237","volume":"31","author":"Zhu Y.","year":"2023","unstructured":"Zhu Y.; Weng X.; Zhang J.; Mao J.; Protective effect of additional cathelicidin antimicrobial peptide PR-39 on prosthetic-joint infections. J Orthop Surg (Hong Kong)  2023,31(2),10225536231175237","journal-title":"J Orthop Surg (Hong Kong)"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"141930","DOI":"10.1016\/j.ijbiomac.2025.141930","volume":"307","author":"Liu Z.","year":"2025","unstructured":"Liu Z.; Qin X.; Zhang B.; Nong K.; Chen W.; Yang Z.; Lang W.; Liu X.; Li L.; Wang X.; Shi H.; Zhang H.; Proline rich-39 (PR-39) antimicrobial protein alleviated lipopolysaccharide-induced intestinal barrier dysfunction in piglets by altering intestinal flora associated bile acid metabolism and in turn regulating TGR-5\/NF-\u03baB\/MLCK\/MLC pathway. Int J Biol Macromol  2025,307(Pt 1),141930","journal-title":"Int J Biol Macromol"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1139\/cjm-2016-0130","volume":"62","author":"Zhang L.","year":"2016","unstructured":"Zhang L.; Guo D.; Liu Y.; Shao Y.; Wang Y.; Xu Y.; Jiang Y.; Cui W.; Li Y.; Tang L.; Probiotic Lactobacillus casei expressing porcine antimicrobial peptide PR39 elevates antibacterial activity in the gastrointestinal tract. Can J Microbiol  2016,62(11),961-969","journal-title":"Can J Microbiol"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s11248-018-0084-z","volume":"27","author":"Zeng F.","year":"2018","unstructured":"Zeng F.; Dong R.; Zhao C.; Liu D.; Zheng E.; Song C.; Wu Z.; Li Z.; Constitutive expression of antimicrobial peptide PR-39 in transgenic mice significantly enhances resistance to bacterial infection and promotes growth. Transgenic Res  2018,27(5),409-422","journal-title":"Transgenic Res"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"e01318-21","DOI":"10.1128\/Spectrum.01318-21","volume":"9","author":"Chen J.","year":"2021","unstructured":"Chen J.; Hao D.; Mei K.; Li X.; Li T.; Ma C.; Xi X.; Li L.; Wang L.; Zhou M.; Chen T.; Liu J.; Wu Q.; In vitro and in vivo studies on the antibacterial activity and safety of a new antimicrobial peptide dermaseptin-AC. Microbiol Spectr  2021,9(3),e01318-21","journal-title":"Microbiol Spectr"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"764","DOI":"10.3389\/fimmu.2020.00764","volume":"11","author":"Xu D.","year":"2020","unstructured":"Xu D.; Lu W.; Defensins: a double-edged sword in host immunity. Front Immunol  2020,11,764","journal-title":"Front Immunol"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2016\/7515687","volume":"2016","author":"Dong H.","year":"2016","unstructured":"Dong H.; Lv Y.; Zhao D.; Barrow P.; Zhou X.; Defensins: the case for their use against mycobacterial infections. J Immunol Res  2016,2016(1),1-9","journal-title":"J Immunol Res"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1080\/13102818.2019.1611385","volume":"33","author":"Amerikova M.","year":"2019","unstructured":"Amerikova M.; Pencheva El-Tibi I.; Maslarska V.; Bozhanov S.; Tachkov K.; Antimicrobial activity, mechanism of action, and methods for stabilisation of defensins as new therapeutic agents. Biotechnol Biotechnol Equip  2019,33(1),671-682","journal-title":"Biotechnol Biotechnol Equip"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.2174\/1381612824666180403114615","volume":"24","author":"Khurshid Z.","year":"2018","unstructured":"Khurshid Z.; Zafar M.S.; Naseem M.; Khan R.S.; Najeeb S.; Human oral defensins antimicrobial peptides: a future promising antimicrobial drug. Curr Pharm Des  2018,24(10),1130-1137","journal-title":"Curr Pharm Des"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3389\/fimmu.2015.00115","volume":"6","author":"Machado L.R.","year":"2015","unstructured":"Machado L.R.; Ottolini B.; An evolutionary history of defensins: a role for copy number variation in maximizing host innate and adaptive immune responses. Front Immunol  2015,6,115","journal-title":"Front Immunol"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"4505","DOI":"10.1128\/IAI.73.8.4505-4511.2005","volume":"73","author":"Rivas-Santiago B.","year":"2005","unstructured":"Rivas-Santiago B.; Schwander S.K.; Sarabia C.; Diamond G.; Klein-Patel M.E.; Hernandez-Pando R.; Ellner J.J.; Sada E.; Human \u03b2-defensin 2 is expressed and associated with Mycobacterium tuberculosis during infection of human alveolar epithelial cells. Infect Immun  2005,73(8),4505-4511","journal-title":"Infect Immun"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"E34","DOI":"10.25011\/cim.v40i1.28052","volume":"40","author":"Majewski K.","year":"2017","unstructured":"Majewski K.; \u017belechowska P.; Brzezi\u0144ska-B\u0142aszczyk E.; Circulating cathelicidin LL-37 in adult patients with pulmonary infectious diseases. Clin Invest Med  2017,40(1),E34-E39","journal-title":"Clin Invest Med"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/j.peptides.2004.04.003","volume":"25","author":"Fattorini L.","year":"2004","unstructured":"Fattorini L.; Gennaro R.; Zanetti M.; Tan D.; Brunori L.; Giannoni F.; Pardini M.; Orefici G.; In vitro activity of protegrin-1 and beta-defensin-1, alone and in combination with isoniazid, against Mycobacterium tuberculosis. Peptides  2004,25(7),1075-1077","journal-title":"Peptides"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1378\/chest.121.2.519","volume":"121","author":"Ashitani J.","year":"2002","unstructured":"Ashitani J.; Mukae H.; Hiratsuka T.; Nakazato M.; Kumamoto K.; Matsukura S.; Elevated levels of \u03b1-defensins in plasma and BAL fluid of patients with active pulmonary tuberculosis. Chest  2002,121(2),519-526","journal-title":"Chest"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1007\/s00109-007-0157-6","volume":"85","author":"Jacobsen M.","year":"2007","unstructured":"Jacobsen M.; Repsilber D.; Gutschmidt A.; Neher A.; Feldmann K.; Mollenkopf H.J.; Ziegler A.; Kaufmann S.H.E.; Candidate biomarkers for discrimination between infection and disease caused by Mycobacterium tuberculosis. J Mol Med (Berl)  2007,85(6),613-621","journal-title":"J Mol Med (Berl)"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1128\/AAC.45.2.639-640.2001","volume":"45","author":"Sharma S.","year":"2001","unstructured":"Sharma S.; Verma I.; Khuller G.K.; Therapeutic potential of human neutrophil peptide 1 against experimental tuberculosis. Antimicrob Agents Chemother  2001,45(2),639-640","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1086\/424463","volume":"190","author":"Kalita A.","year":"2004","unstructured":"Kalita A.; Verma I.; Khuller G.K.; Role of human neutrophil peptide-1 as a possible adjunct to antituberculosis chemotherapy. J Infect Dis  2004,190(8),1476-1480","journal-title":"J Infect Dis"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"7866","DOI":"10.1038\/s41598-019-44256-6","volume":"9","author":"Sharma R.","year":"2019","unstructured":"Sharma R.; Raghav R.; Priyanka K.; Rishi P.; Sharma S.; Srivastava S.; Verma I.; Exploiting chitosan and gold nanoparticles for antimycobacterial activity of in silico identified antimicrobial motif of human neutrophil peptide-1. Sci Rep  2019,9(1),7866","journal-title":"Sci Rep"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.3390\/vetsci12111030","volume":"12","author":"Xu J.","year":"2025","unstructured":"Xu J.; He Y.; Liang Z.; Chen S.; Tang B.; Su F.; Liu C.; Protegrin-1 combats multidrug-resistant porcine ExPEC: Potent bactericidal activity and multimodal immunometabolic regulation in vitro and in a murine model. Vet Sci  2025,12(11),1030","journal-title":"Vet Sci"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.molimm.2024.07.011","volume":"173","author":"Javed A.","year":"2024","unstructured":"Javed A.; Oedairadjsingh T.; Ludwig I.S.; Wood T.M.; Martin N.I.; Broere F.; Weingarth M.H.; Veldhuizen E.J.A.; Antimicrobial and immunomodulatory activities of porcine cathelicidin Protegrin-1. Mol Immunol  2024,173,100-109","journal-title":"Mol Immunol"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"106931","DOI":"10.1016\/j.micpath.2024.106931","volume":"196","author":"Hosseini Goki N.","year":"2024","unstructured":"Hosseini Goki N.; Saberi M.R.; Amin M.; Fazly Bazzaz B.S.; Khameneh B.; Novel antimicrobial peptides based on Protegrin-1: In silico and in vitro assessments. Microb Pathog  2024,196,106931","journal-title":"Microb Pathog"},{"key":"ref=90","doi-asserted-by":"publisher","DOI":"10.1128\/microbiolspec.RWR-0010-2017","volume":"6","author":"Chareyre S.","year":"2018","unstructured":"Chareyre S.; Mandin P.; Bacterial iron homeostasis regulation by sRNAs. Microbiol Spectr  2018,6(2),10.1128\/microbiolspec.rwr-0010-2017.","journal-title":"Microbiol Spectr"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1159\/000315436","volume":"33","author":"Malyszko J.","year":"2010","unstructured":"Malyszko J.; Tesa\u0159 V.; Macdougall I.C.; Neutrophil gelatinase-associated lipocalin and hepcidin: what do they have in common and is there a potential interaction? Kidney Blood Press Res  2010,33(2),157-165","journal-title":"Kidney Blood Press Res"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1159\/000243791","volume":"122","author":"Nemeth E.","year":"2009","unstructured":"Nemeth E.; Ganz T.; The role of hepcidin in iron metabolism. Acta Haematol  2009,122(2-3),78-86","journal-title":"Acta Haematol"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"84","DOI":"10.3390\/ph11030084","volume":"11","author":"Gomes A.C.","year":"2018","unstructured":"Gomes A.C.; Moreira A.C.; Mesquita G.; Gomes M.S.; Modulation of iron metabolism in response to infection: twists for all tastes. Pharmaceuticals (Basel)  2018,11(3),84","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1189\/jlb.0407216","volume":"82","author":"Sow F.B.","year":"2007","unstructured":"Sow F.B.; Florence W.C.; Satoskar A.R.; Schlesinger L.S.; Zwilling B.S.; Lafuse W.P.; Expression and localization of hepcidin in macrophages: a role in host defense against tuberculosis. J Leukoc Biol  2007,82(4),934-945","journal-title":"J Leukoc Biol"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"e0191038","DOI":"10.1371\/journal.pone.0191038","volume":"13","author":"Harrington-Kandt R.","year":"2018","unstructured":"Harrington-Kandt R.; Stylianou E.; Eddowes L.A.; Lim P.J.; Stockdale L.; Pinpathomrat N.; Bull N.; Pasricha J.; Ulaszewska M.; Beglov Y.; Vaulont S.; Drakesmith H.; McShane H.; Hepcidin deficiency and iron deficiency do not alter tuberculosis susceptibility in a murine M.tb infection model. PLoS One  2018,13(1),e0191038","journal-title":"PLoS One"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"11264","DOI":"10.3390\/ijms222011264","volume":"22","author":"Gruden \u0160.","year":"2021","unstructured":"Gruden \u0160.; Poklar Ulrih N.; Diverse mechanisms of antimicrobial activities of lactoferrins, lactoferricins, and other lactoferrin-derived peptides. Int J Mol Sci  2021,22(20),11264","journal-title":"Int J Mol Sci"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"752","DOI":"10.3390\/molecules21060752","volume":"21","author":"Bruni N.","year":"2016","unstructured":"Bruni N.; Capucchio M.; Biasibetti E.; Pessione E.; Cirrincione S.; Giraudo L.; Corona A.; Dosio F.; Antimicrobial activity of lactoferrin-related peptides and applications in human and veterinary medicine. Molecules  2016,21(6),752","journal-title":"Molecules"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"e24122","DOI":"10.1002\/pep2.24122","volume":"111","author":"Koo H.B.","year":"2019","unstructured":"Koo H.B.; Seo J.; Antimicrobial peptides under clinical investigation. Pept Sci (Hoboken)  2019,111(5),e24122","journal-title":"Pept Sci (Hoboken)"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"e00301-17","DOI":"10.1128\/mSphere.00301-17","volume":"2","author":"Silva T.","year":"2017","unstructured":"Silva T.; Moreira A.C.; Nazmi K.; Moniz T.; Vale N.; Rangel M.; Gomes P.; Bolscher J.G.M.; Rodrigues P.N.; Bastos M.; Gomes M.S.; Lactoferricin peptides increase macrophages\u2019 capacity to kill Mycobacterium avium. MSphere  2017,2(4),e00301-17","journal-title":"MSphere"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"3461","DOI":"10.1128\/AAC.02728-13","volume":"58","author":"Silva T.","year":"2014","unstructured":"Silva T.; Magalh\u00e3es B.; Maia S.; Gomes P.; Nazmi K.; Bolscher J.G.M.; Rodrigues P.N.; Bastos M.; Gomes M.S.; Killing of Mycobacterium avium by lactoferricin peptides: improved activity of arginine- and D-amino-acid-containing molecules. Antimicrob Agents Chemother  2014,58(6),3461-3467","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s10989-010-9211-2","volume":"16","author":"Fornili S.L.","year":"2010","unstructured":"Fornili S.L.; Pizzi R.; Rebeccani D.; Conformational analysis of a synthetic antimicrobial peptide in water and membrane-mimicking solvents: a molecular dynamics simulation study. Int J Pept Res Ther  2010,16(4),223-231","journal-title":"Int J Pept Res Ther"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1111\/ijfs.13392","volume":"52","author":"Welsh G.","year":"2017","unstructured":"Welsh G.; Ryder K.; Brewster J.; Walker C.; Mros S.; Bekhit A.E.D.A.; McConnell M.; Carne A.; Comparison of bioactive peptides prepared from sheep cheese whey using a food-grade bacterial and a fungal protease preparation. Int J Food Sci Technol  2017,52(5),1252-1259","journal-title":"Int J Food Sci Technol"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s00430-007-0041-6","volume":"196","author":"Hwang S.A.","year":"2007","unstructured":"Hwang S.A.; Wilk K.M.; Bangale Y.A.; Kruzel M.L.; Actor J.K.; Lactoferrin modulation of IL-12 and IL-10 response from activated murine leukocytes. Med Microbiol Immunol (Berl)  2007,196(3),171-180","journal-title":"Med Microbiol Immunol (Berl)"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1177\/0394632015599832","volume":"28","author":"Hwang S.A.","year":"2015","unstructured":"Hwang S.A.; Kruzel M.L.; Actor J.K.; CHO expressed recombinant human lactoferrin as an adjuvant for BCG. Int J Immunopathol Pharmacol  2015,28(4),452-468","journal-title":"Int J Immunopathol Pharmacol"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"3159","DOI":"10.1016\/j.vaccine.2012.03.008","volume":"30","author":"Thom R.E.","year":"2012","unstructured":"Thom R.E.; Elmore M.J.; Williams A.; Andrews S.C.; Drobniewski F.; Marsh P.D.; Tree J.A.; The expression of ferritin, lactoferrin, transferrin receptor and solute carrier family 11A1 in the host response to BCG-vaccination and Mycobacterium tuberculosis challenge. Vaccine  2012,30(21),3159-3168","journal-title":"Vaccine"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"245","DOI":"10.3389\/fcimb.2017.00245","volume":"7","author":"Malhotra H.","year":"2017","unstructured":"Malhotra H.; Patidar A.; Boradia V.M.; Kumar R.; Nimbalkar R.D.; Kumar A.; Gani Z.; Kaur R.; Garg P.; Raje M.; Raje C.I.; Mycobacterium tuberculosis glyceraldehyde-3-phosphate dehydrogenase (GAPDH) functions as a receptor for human lactoferrin. Front Cell Infect Microbiol  2017,7,245","journal-title":"Front Cell Infect Microbiol"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"437","DOI":"10.4161\/bbug.1.6.13855","volume":"1","author":"Donaghy J.","year":"2010","unstructured":"Donaghy J.; Lantibiotics as prospective antimycobacterial agents. Bioeng Bugs  2010,1(6),437-439","journal-title":"Bioeng Bugs"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.tifs.2009.01.056","volume":"20","author":"de Arauz L.J.","year":"2009","unstructured":"de Arauz L.J.; Jozala A.F.; Mazzola P.G.; Vessoni Penna T.C.; Nisin biotechnological production and application: a review. Trends Food Sci Technol  2009,20(3-4),146-154","journal-title":"Trends Food Sci Technol"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"193","DOI":"10.2174\/138920312800785021","volume":"13","author":"Suda S.","year":"2012","unstructured":"Suda S.; Cotter P.D.; Hill C.; Ross R.P.; Lacticin 3147--biosynthesis, molecular analysis, immunity, bioengineering and applications. Curr Protein Pept Sci  2012,13(3),193-204","journal-title":"Curr Protein Pept Sci"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ijantimicag.2010.03.029","volume":"36","author":"Carroll J.","year":"2010","unstructured":"Carroll J.; Draper L.A.; O\u2019Connor P.M.; Coffey A.; Hill C.; Ross R.P.; Cotter P.D.; O\u2019Mahony J.; Comparison of the activities of the lantibiotics nisin and lacticin 3147 against clinically significant mycobacteria. Int J Antimicrob Agents  2010,36(2),132-136","journal-title":"Int J Antimicrob Agents"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"408","DOI":"10.4161\/bbug.1.6.13642","volume":"1","author":"Carroll J.","year":"2010","unstructured":"Carroll J.; Field D.; O\u2019 Connor P.M.; Cotter P.D.; Coffey A.; Hill C.; O\u2019 Mahony J.; O\u2019Mahony J.; The gene encoded antimicrobial peptides, a template for the design of novel anti-mycobacterial drugs. Bioeng Bugs  2010,1(6),408-412","journal-title":"Bioeng Bugs"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1002\/jps.22015","volume":"99","author":"Ghobrial O.","year":"2010","unstructured":"Ghobrial O.; Derendorf H.; Hillman J.D.; Pharmacokinetic and pharmacodynamic evaluation of the lantibiotic MU1140. J Pharm Sci  2010,99(5),2521-2528","journal-title":"J Pharm Sci"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"e2421164122","DOI":"10.1073\/pnas.2421164122","volume":"122","author":"Wyllie R.M.","year":"2025","unstructured":"Wyllie R.M.; Jensen P.A.; The MutRS quorum-sensing system controls lantibiotic mutacin production in the human pathogen Streptococcus mutans. Proc Natl Acad Sci USA  2025,122(7),e2421164122","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"3308","DOI":"10.1021\/bi701262z","volume":"47","author":"Smith L.","year":"2008","unstructured":"Smith L.; Hasper H.; Breukink E.; Novak J.; \u010cerkasov J.; Hillman J.D.; Wilson-Stanford S.; Orugunty R.S.; Elucidation of the antimicrobial mechanism of mutacin 1140. Biochemistry  2008,47(10),3308-3314","journal-title":"Biochemistry"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"3931","DOI":"10.1007\/s00253-019-09771-6","volume":"103","author":"Zhu S.","year":"2019","unstructured":"Zhu S.; Su Y.; Shams S.; Feng Y.; Tong Y.; Zheng G.; Lassomycin and lariatin lasso peptides as suitable antibiotics for combating mycobacterial infections: current state of biosynthesis and perspectives for production. Appl Microbiol Biotechnol  2019,103(10),3931-3940","journal-title":"Appl Microbiol Biotechnol"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.chembiol.2014.01.014","volume":"21","author":"Gavrish E.","year":"2014","unstructured":"Gavrish E.; Sit C.S.; Cao S.; Kandror O.; Spoering A.; Peoples A.; Ling L.; Fetterman A.; Hughes D.; Bissell A.; Torrey H.; Akopian T.; Mueller A.; Epstein S.; Goldberg A.; Clardy J.; Lewis K.; Lassomycin, a ribosomally synthesized cyclic peptide, kills mycobacterium tuberculosis by targeting the ATP-dependent protease ClpC1P1P2. Chem Biol  2014,21(4),509-518","journal-title":"Chem Biol"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"8379","DOI":"10.1074\/jbc.RA118.002251","volume":"293","author":"Weinh\u00e4upl K.","year":"2018","unstructured":"Weinh\u00e4upl K.; Brennich M.; Kazmaier U.; Lelievre J.; Ballell L.; Goldberg A.; Schanda P.; Fraga H.; The antibiotic cyclomarin blocks arginine-phosphate\u2013induced millisecond dynamics in the N-terminal domain of ClpC1 from Mycobacterium tuberculosis. J Biol Chem  2018,293(22),8379-8393","journal-title":"J Biol Chem"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/ja.2007.48","volume":"60","author":"Iwatsuki M.","year":"2007","unstructured":"Iwatsuki M.; Uchida R.; Takakusagi Y.; Matsumoto A.; Jiang C.L.; Takahashi Y.; Arai M.; Kobayashi S.; Matsumoto M.; Inokoshi J.; Tomoda H.; \u014cmura S.; Lariatins, novel anti-mycobacterial peptides with a lasso structure, produced by Rhodococcus jostii K01-B0171. J Antibiot (Tokyo)  2007,60(6),357-363","journal-title":"J Antibiot (Tokyo)"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"323","DOI":"10.3390\/ph14040323","volume":"14","author":"Oliveira G.S.","year":"2021","unstructured":"Oliveira G.S.; Costa R.P.; Gomes P.; Gomes M.S.; Silva T.; Teixeira C.; Antimicrobial peptides as potential anti-tubercular leads: a concise review. Pharmaceuticals (Basel)  2021,14(4),323","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"e00860-20","DOI":"10.1128\/AAC.00860-20","volume":"64","author":"Cohen K.A.","year":"2020","unstructured":"Cohen K.A.; Stott K.E.; Munsamy V.; Manson A.L.; Earl A.M.; Pym A.S.; Evidence for expanding the role of streptomycin in the management of drug-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother  2020,64(9),e00860-20","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1021\/np400145u","volume":"76","author":"Cai G.","year":"2013","unstructured":"Cai G.; Napolitano J.G.; McAlpine J.B.; Wang Y.; Jaki B.U.; Suh J.W.; Yang S.H.; Lee I.A.; Franzblau S.G.; Pauli G.F.; Cho S.; Hytramycins V and I, anti-Mycobacterium tuberculosis hexapeptides from a Streptomyces hygroscopicus strain. J Nat Prod  2013,76(11),2009-2018","journal-title":"J Nat Prod"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"5889","DOI":"10.1002\/anie.201101740","volume":"50","author":"Schmitt E.K.","year":"2011","unstructured":"Schmitt E.K.; Riwanto M.; Sambandamurthy V.; Roggo S.; Miault C.; Zwingelstein C.; Krastel P.; Noble C.; Beer D.; Rao S.P.S.; Au M.; Niyomrattanakit P.; Lim V.; Zheng J.; Jeffery D.; Pethe K.; Camacho L.R.; The natural product cyclomarin kills Mycobacterium tuberculosis by targeting the ClpC1 subunit of the caseinolytic protease. Angew Chem Int Ed  2011,50(26),5889-5891","journal-title":"Angew Chem Int Ed"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"6804","DOI":"10.1016\/j.bmcl.2011.09.031","volume":"21","author":"Li Y.B.","year":"2011","unstructured":"Li Y.B.; Xie Y.Y.; Du N.N.; Lu Y.; Xu H.Z.; Wang B.; Yu Y.; Liu Y.X.; Song D.Q.; Chen R.X.; Synthesis and in vitro antitubercular evaluation of novel sansanmycin derivatives. Bioorg Med Chem Lett  2011,21(22),6804-6807","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.tube.2018.10.008","volume":"113","author":"Tenland E.","year":"2018","unstructured":"Tenland E.; Krishnan N.; R\u00f6nnholm A.; Kalsum S.; Puthia M.; M\u00f6rgelin M.; Davoudi M.; Otrocka M.; Alaridah N.; Glegola-Madejska I.; Stureg\u00e5rd E.; Schmidtchen A.; Lerm M.; Robertson B.D.; Godaly G.; A novel derivative of the fungal antimicrobial peptide plectasin is active against Mycobacterium tuberculosis. Tuberculosis (Edinb)  2018,113,231-238","journal-title":"Tuberculosis (Edinb)"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1080\/10942912.2010.509896","volume":"15","author":"Koffi-Nevry R.","year":"2012","unstructured":"Koffi-Nevry R.; Kouassi K.C.; Nanga Z.Y.; Kouss\u00e9mon M.; Loukou G.Y.; Antibacterial activity of two bell pepper extracts: Capsicum annuum L. and Capsicum frutescens. Int J Food Prop  2012,15(5),961-971","journal-title":"Int J Food Prop"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1007\/s11418-011-0579-x","volume":"66","author":"Santos M.M.P.","year":"2012","unstructured":"Santos M.M.P.; Vieira-da-Motta O.; Vieira I.J.C.; Braz-Filho R.; Gon\u00e7alves P.S.; Maria E.J.; Terra W.S.; Rodrigues R.; Souza C.L.M.; Antibacterial activity of Capsicum annuum extract and synthetic capsaicinoid derivatives against Streptococcus mutans. J Nat Med  2012,66(2),354-356","journal-title":"J Nat Med"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1007\/s12602-020-09647-6","volume":"12","author":"da Silva Gebara R.","year":"2020","unstructured":"da Silva Gebara R.; Taveira G.B.; de Azevedo dos Santos L.; Calixto S.D.; Sim\u00e3o T.L.B.V.; Lassounskaia E.; Muzitano M.F.; Teixeira-Ferreira A.; Perales J.; Rodrigues R.; de Oliveira Carvalho A.; Gomes V.M.; Identification and characterization of two defensins from Capsicum annuum fruits that exhibit antimicrobial activity. Probiotics Antimicrob Proteins  2020,12(3),1253-1265","journal-title":"Probiotics Antimicrob Proteins"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s43088-020-00093-5","volume":"10","author":"Azmi S.","year":"2021","unstructured":"Azmi S.; Hussain M.K.; Analysis of structures, functions, and transgenicity of phytopeptides defensin and thionin: a review. Beni Suef Univ J Basic Appl Sci  2021,10(1),5","journal-title":"Beni Suef Univ J Basic Appl Sci"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"5092","DOI":"10.1007\/s10528-024-10695-8","volume":"62","author":"Mir Drikvand R.","year":"2024","unstructured":"Mir Drikvand R.; Sohrabi S.M.; Sohrabi S.S.; Samiei K.; Molecular identification and characterization of hevein antimicrobial peptide genes in two-row and six-row cultivars of barley (Hordeum vulgare L.). Biochem Genet  2024,62(6),5092-5114","journal-title":"Biochem Genet"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"4801","DOI":"10.1093\/jxb\/erw210","volume":"67","author":"Weidmann J.","year":"2016","unstructured":"Weidmann J.; Craik D.J.; Discovery, structure, function, and applications of cyclotides: circular proteins from plants. J Exp Bot  2016,67(16),4801-4812","journal-title":"J Exp Bot"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"100252","DOI":"10.1016\/j.mocell.2025.100252","volume":"48","author":"Hyun Y.","year":"2025","unstructured":"Hyun Y.; Cyclotides as novel plant-derived scaffolds for orally active cyclic peptide therapeutics. Mol Cells  2025,48(9),100252","journal-title":"Mol Cells"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"3547","DOI":"10.1016\/j.jmb.2018.12.015","volume":"431","author":"Torres M.D.T.","year":"2019","unstructured":"Torres M.D.T.; Sothiselvam S.; Lu T.K.; de la Fuente-Nunez C.; Peptide design principles for antimicrobial applications. J Mol Biol  2019,431(18),3547-3567","journal-title":"J Mol Biol"},{"key":"ref=133","doi-asserted-by":"crossref","unstructured":"Costa, F.; Teixeira, C.; Gomes, P.; Martins, M.C.L. Clinical Application of AMPs. In: Matsuzaki, K. eds. Antimicrobial Peptides. Advances in Experimental Medicine and Biology, Springer, Singapore, 2019.","DOI":"10.1007\/978-981-13-3588-4_15"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"2732","DOI":"10.2174\/138161211797416066","volume":"17","author":"Dohm M.T.","year":"2011","unstructured":"Dohm M.T.; Kapoor R.; Barron A.E.; Peptoids: bio-inspired polymers as potential pharmaceuticals. Curr Pharm Des  2011,17(25),2732-2747","journal-title":"Curr Pharm Des"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"3058","DOI":"10.1128\/AAC.01667-10","volume":"55","author":"Kapoor R.","year":"2011","unstructured":"Kapoor R.; Eimerman P.R.; Hardy J.W.; Cirillo J.D.; Contag C.H.; Barron A.E.; Efficacy of antimicrobial peptoids against Mycobacterium tuberculosis. Antimicrob Agents Chemother  2011,55(6),3058-3062","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"4056","DOI":"10.1016\/j.bmc.2016.06.048","volume":"24","author":"Hicks R.P.","year":"2016","unstructured":"Hicks R.P.; Antibacterial and anticancer activity of a series of novel peptides incorporating cyclic tetra-substituted C\u03b1 amino acids. Bioorg Med Chem  2016,24(18),4056-4065","journal-title":"Bioorg Med Chem"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1016\/j.biomaterials.2013.11.035","volume":"35","author":"Khara J.S.","year":"2014","unstructured":"Khara J.S.; Wang Y.; Ke X.Y.; Liu S.; Newton S.M.; Langford P.R.; Yang Y.Y.; Ee P.L.R.; Anti-mycobacterial activities of synthetic cationic \u03b1-helical peptides and their synergism with rifampicin. Biomaterials  2014,35(6),2032-2038","journal-title":"Biomaterials"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"34120","DOI":"10.1074\/jbc.M112.359067","volume":"287","author":"Vermeer L.S.","year":"2012","unstructured":"Vermeer L.S.; Lan Y.; Abbate V.; Ruh E.; Bui T.T.; Wilkinson L.J.; Kanno T.; Jumagulova E.; Kozlowska J.; Patel J.; McIntyre C.A.; Yam W.C.; Siu G.; Atkinson R.A.; Lam J.K.W.; Bansal S.S.; Drake A.F.; Mitchell G.H.; Mason A.J.; Conformational flexibility determines selectivity and antibacterial, antiplasmodial, and anticancer potency of cationic \u03b1-helical peptides. J Biol Chem  2012,287(41),34120-34133","journal-title":"J Biol Chem"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/j.tube.2014.08.001","volume":"94","author":"Lan Y.","year":"2014","unstructured":"Lan Y.; Lam J.T.; Siu G.K.H.; Yam W.C.; Mason A.J.; Lam J.K.W.; Cationic amphipathic D-enantiomeric antimicrobial peptides with in vitro and ex vivo activity against drug-resistant Mycobacterium tuberculosis. Tuberculosis (Edinb)  2014,94(6),678-689","journal-title":"Tuberculosis (Edinb)"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1128\/AAC.00175-13","volume":"57","author":"Ram\u00f3n-Garc\u00eda S.","year":"2013","unstructured":"Ram\u00f3n-Garc\u00eda S.; Mikut R.; Ng C.; Ruden S.; Volkmer R.; Reischl M.; Hilpert K.; Thompson C.J.; Targeting Mycobacterium tuberculosis and other microbial pathogens using improved synthetic antibacterial peptides. Antimicrob Agents Chemother  2013,57(5),2295-2303","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.jgar.2019.04.018","volume":"19","author":"Silva S.","year":"2019","unstructured":"Silva S.; Santos-Silva A.; da Costa J.M.C.; Vale N.; Potent cationic antimicrobial peptides against Mycobacterium tuberculosis in vitro. J Glob Antimicrob Resist  2019,19,132-135","journal-title":"J Glob Antimicrob Resist"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"e59119","DOI":"10.1371\/journal.pone.0059119","volume":"8","author":"Rivas-Santiago B.","year":"2013","unstructured":"Rivas-Santiago B.; Casta\u00f1eda-Delgado J.E.; Rivas Santiago C.E.; Waldbrook M.; Gonz\u00e1lez-Curiel I.; Le\u00f3n-Contreras J.C.; Enciso-Moreno J.A.; Villar V.; Mendez-Ramos J.; Hancock R.E.W.; Hernandez-Pando R.; Ability of innate defence regulator peptides IDR-1002, IDR-HH2 and IDR-1018 to protect against Mycobacterium tuberculosis infections in animal models. PLoS One  2013,8(3),e59119","journal-title":"PLoS One"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"7615","DOI":"10.1074\/jbc.RA118.006968","volume":"294","author":"Yang Y.","year":"2019","unstructured":"Yang Y.; Liu Z.; He X.; Yang J.; Wu J.; Yang H.; Li M.; Qian Q.; Lai R.; Xu W.; Wei L.; A small mycobacteriophage-derived peptide and its improved isomer restrict mycobacterial infection via dual mycobactericidal-immunoregulatory activities. J Biol Chem  2019,294(19),7615-7631","journal-title":"J Biol Chem"},{"key":"ref=144","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/nchembio.1120","volume":"9","author":"Slavoff S.A.","year":"2013","unstructured":"Slavoff S.A.; Mitchell A.J.; Schwaid A.G.; Cabili M.N.; Ma J.; Levin J.Z.; Karger A.D.; Budnik B.A.; Rinn J.L.; Saghatelian A.; Peptidomic discovery of short open reading frame\u2013encoded peptides in human cells. Nat Chem Biol  2013,9(1),59-64","journal-title":"Nat Chem Biol"},{"key":"ref=145","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1039\/C2NP20085F","volume":"30","author":"Arnison P.G.","year":"2013","unstructured":"Arnison P.G.; Bibb M.J.; Bierbaum G.; Bowers A.A.; Bugni T.S.; Bulaj G.; Camarero J.A.; Campopiano D.J.; Challis G.L.; Clardy J.; Cotter P.D.; Craik D.J.; Dawson M.; Dittmann E.; Donadio S.; Dorrestein P.C.; Entian K.D.; Fischbach M.A.; Garavelli J.S.; G\u00f6ransson U.; Gruber C.W.; Haft D.H.; Hemscheidt T.K.; Hertweck C.; Hill C.; Horswill A.R.; Jaspars M.; Kelly W.L.; Klinman J.P.; Kuipers O.P.; Link A.J.; Liu W.; Marahiel M.A.; Mitchell D.A.; Moll G.N.; Moore B.S.; M\u00fcller R.; Nair S.K.; Nes I.F.; Norris G.E.; Olivera B.M.; Onaka H.; Patchett M.L.; Piel J.; Reaney M.J.T.; Rebuffat S.; Ross R.P.; Sahl H.G.; Schmidt E.W.; Selsted M.E.; Severinov K.; Shen B.; Sivonen K.; Smith L.; Stein T.; S\u00fcssmuth R.D.; Tagg J.R.; Tang G.L.; Truman A.W.; Vederas J.C.; Walsh C.T.; Walton J.D.; Wenzel S.C.; Willey J.M.; van der Donk W.A.; Ribosomally synthesized and post-translationally modified peptide natural products: overview and recommendations for a universal nomenclature. Nat Prod Rep  2013,30(1),108-160","journal-title":"Nat Prod Rep"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.cell.2019.05.010","volume":"178","author":"van Heesch S.","year":"2019","unstructured":"van Heesch S.; Witte F.; Schneider-Lunitz V.; Schulz J.F.; Adami E.; Faber A.B.; Kirchner M.; Maatz H.; Blachut S.; Sandmann C.L.; Kanda M.; Worth C.L.; Schafer S.; Calviello L.; Merriott R.; Patone G.; Hummel O.; Wyler E.; Obermayer B.; M\u00fccke M.B.; Lindberg E.L.; Trnka F.; Memczak S.; Schilling M.; Felkin L.E.; Barton P.J.R.; Quaife N.M.; Vanezis K.; Diecke S.; Mukai M.; Mah N.; Oh S.J.; Kurtz A.; Schramm C.; Schwinge D.; Sebode M.; Harakalova M.; Asselbergs F.W.; Vink A.; de Weger R.A.; Viswanathan S.; Widjaja A.A.; G\u00e4rtner-Rommel A.; Milting H.; dos Remedios C.; Knosalla C.; Mertins P.; Landthaler M.; Vingron M.; Linke W.A.; Seidman J.G.; Seidman C.E.; Rajewsky N.; Ohler U.; Cook S.A.; Hubner N.; The translational landscape of the human heart. Cell  2019,178(1),242-260.e29","journal-title":"Cell"},{"key":"ref=147","doi-asserted-by":"publisher","first-page":"e03523","DOI":"10.7554\/eLife.03523","volume":"3","author":"Ruiz-Orera J.","year":"2014","unstructured":"Ruiz-Orera J.; Messeguer X.; Subirana J.A.; Alb\u00e0 M.M.; Long non-coding RNAs as a source of new peptides. eLife  2014,3,e03523","journal-title":"eLife"},{"key":"ref=148","doi-asserted-by":"publisher","first-page":"100375","DOI":"10.1016\/j.xgen.2023.100375","volume":"3","author":"Guig\u00f3 R.","year":"2023","unstructured":"Guig\u00f3 R.; Genome annotation: From human genetics to biodiversity genomics. Cell Genomics  2023,3(8),100375","journal-title":"Cell Genomics"},{"key":"ref=149","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/s41551-021-00689-x","volume":"5","author":"Das P.","year":"2021","unstructured":"Das P.; Sercu T.; Wadhawan K.; Padhi I.; Gehrmann S.; Cipcigan F.; Chenthamarakshan V.; Strobelt H.; dos Santos C.; Chen P.Y.; Yang Y.Y.; Tan J.P.K.; Hedrick J.; Crain J.; Mojsilovic A.; Accelerated antimicrobial discovery via deep generative models and molecular dynamics simulations. Nat Biomed Eng  2021,5(6),613-623","journal-title":"Nat Biomed Eng"},{"key":"ref=150","doi-asserted-by":"crossref","unstructured":"Farnia, P.; Velayati, A. A.; Ghanavi, J.; Farnia, P. Proteins in Mycobacterium tuberculosis: Functions and therapeutic advances; Springer Nature, 2025.","DOI":"10.1007\/978-3-031-96883-9"},{"key":"ref=151","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/s41597-019-0154-y","volume":"6","author":"Kang X.","year":"2019","unstructured":"Kang X.; Dong F.; Shi C.; Liu S.; Sun J.; Chen J.; Li H.; Xu H.; Lao X.; Zheng H.; DRAMP 2.0, an updated data repository of antimicrobial peptides. Sci Data  2019,6(1),148","journal-title":"Sci Data"},{"key":"ref=152","doi-asserted-by":"publisher","first-page":"102440","DOI":"10.1016\/j.omtn.2024.102440","volume":"36","author":"Naeem S.","year":"2025","unstructured":"Naeem S.; Zhang J.; Zhang Y.; Wang Y.; Nucleic acid therapeutics: Past, present, and future. Mol Ther Nucleic Acids  2025,36(1),102440","journal-title":"Mol Ther Nucleic Acids"},{"key":"ref=153","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1080\/17460441.2022.2108785","volume":"17","author":"Winkler D.A.","year":"2022","unstructured":"Winkler D.A.; The impact of machine learning on future tuberculosis drug discovery. Expert Opin Drug Discov  2022,17(9),925-927","journal-title":"Expert Opin Drug Discov"},{"key":"ref=154","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/nrd3591","volume":"11","author":"Fjell C.D.","year":"2012","unstructured":"Fjell C.D.; Hiss J.A.; Hancock R.E.W.; Schneider G.; Designing antimicrobial peptides: form follows function. Nat Rev Drug Discov  2012,11(1),37-51","journal-title":"Nat Rev Drug Discov"},{"key":"ref=155","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.drudis.2009.10.009","volume":"15","author":"Vlieghe P.","year":"2010","unstructured":"Vlieghe P.; Lisowski V.; Martinez J.; Khrestchatisky M.; Synthetic therapeutic peptides: science and market. Drug Discov Today  2010,15(1-2),40-56","journal-title":"Drug Discov Today"}],"container-title":["Current Protein &amp; Peptide Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0113892037433604260409094048","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/252630\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0113892037433604260409094048","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T05:24:29Z","timestamp":1793337869000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/252630\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":155,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0113892037433604260409094048","relation":{},"ISSN":["1389-2037"],"issn-type":[{"value":"1389-2037","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Double blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2025-09-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-10","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}